By Kama Witkowska Marketing and Communication Manager What is chronic kidney disease (CKD)? Chronic kidney disease (CKD) is a progressive condition where the kidneys gradually lose function [1]. It is characterized by a high morbidity and mortality rate, and it is predicted to be the 5th leading cause of death globally by 2040 [2]. It commonly affects [...]
By now, AI’s ability to enhance diagnostic efficiency and reduce cancer detection errors is well documented, delivering benefits to pathologists and patients globally. Still, these outcomes are only the beginning of what AI can offer to the field of cancer care. Beyond replicating tasks humans can do without AI assistance, albeit with more time and less consistency, AI’s true power lies in its ability to uncover revolutionary new insights – insights that could change the way we understand this complex disease and empower more precise, effective treatments.
Indica Labs has announced the expansion of their reseller network in the Asia Pacific (APAC) region. New distributorship agreements have been inked with MRL Cybertec Corporation, Pathology Ware International, Minh Khang Technical Service & Trading Co. Ltd., and Histocenter, for distribution in the Philippines, Thailand, Vietnam, and Malaysia, respectively. The new partnerships build upon Indica’s previous commercial success in China and Japan where sales have grown substantially in recent years.
Roche announced that the WHO has prequalified the cobas® HPV test for use on the cobas® 5800 system and for self-collected samples on the cobas® 5800, 6800, and 8800 systems. This follows the recent FDA approval of Roche’s HPV self-collection solution and the WHO’s earlier prequalification for the cobas 6800/8800 systems.
Cytological evaluation of fine needle aspirates can provide critical information to veterinary practitioners, for example in the detection of mast cell neoplasia. However, in some cases the cytological evaluation does not provide a definitive diagnosis, but it can give us some useful information and help us to determine the next step. In these instances, it is important to have a differential list in mind and to communicate this to the client.
In a new study, researchers at the University of Cambridge and Bispebjerg University Hospital developed a digital quantification pipeline using machine learning to quantify different types of tau pathology in postmortem brain samples from patients with progressive supranuclear palsy (PSP), a neurodegenerative tauopathy.
Unlocks Efficiency Gains with High-Speed Search, Easy Metadata Tagging, and On-Platform AI Analysis NEW YORK CITY (June 27, 2024) -- HistoWiz, a leader in digital pathology services, introduces PathologyMap™ 2.0, its next-generation digital slide management solution which leverages advanced AI and metadata analysis to build on the original’s data viewing, tagging, annotation, and sharing features for [...]
Indica Labs, the global leader in AI-powered digital pathology software and services, is proud to announce that they have been awarded a Top Workplaces™ honor by The Albuquerque Journal for a fifth consecutive year. In 2024, Indica Labs climbed in the rankings of equivalently sized employers, placing fifth out of 39 awardees.
Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, has expanded its leadership position in the diagnostic pathology market. The company has grown its clinical customer base by more than 100% in the past year. Among its other highlights, Proscia was recognized by KLAS Research in a June 2024 Emerging Company Spotlight report and released findings from a study conducted with Quest Diagnostics, a leading provider of diagnostic information services, on the impact of its AI-enabled workflows.
Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, has partnered with Nucleai, a leading spatial AI biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes. At the center of the collaboration, the companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq® software platform and make them available as part of Proscia’s precision medicine AI portfolio to better inform patient care.
